Diabetic Macular Edema (DME) Completed Phase 1 / 2 Trials for Ranibizumab (DB01270)

Also known as: Diabetic Macular Edema(DME) / Diabetic Macular Oedema / Macular Edema, Diabetic / Diabetic Macular Edema / Macular edema due to diabetes mellitus (disorder) / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02448446The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid ExudatesTreatment
NCT02118831Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFBasic Science
NCT01982435Safety and Efficacy of Ranibizumab for Diabetic Macular EdemaTreatment
NCT01934556A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular EdemaTreatment
NCT01552408Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)Treatment
NCT01292798Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to BevacizumabTreatment